Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

Trial Profile

Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs EB 001 (Primary)
  • Indications Glabellar lines
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Bonti
  • Most Recent Events

    • 09 Aug 2017 According to a Bonti media release, Dr. Steve Yoelin is one of the principal investigators.
    • 09 Aug 2017 Results published in a Bonti Media Release.
    • 03 May 2017 According to a Bonti media release, a total of 24 subjects in 4 cohorts have been treated to date (20 received active drug, 4 received placebo).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top